Claudio Bomio-Confaglia

Claudio Bomio-Confaglia

Auto-generated profile, based on publicly available information

Claudio Bomio-Confaglia

Novartis Biomedical Research

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AWAndreas Weiss
Andreas Weiss
ELEdwige Lorthiois
Edwige Lorthiois
LBLouise Barys
Louise Barys
KBKim S. Beyer
Kim S. Beyer
CBClaudio Bomio-Confaglia
Claudio Bomio-Confaglia
SBSaskia M. Brachmann
Saskia M. Brachmann
Covalent inhibitors of KRASG12C have shown antitumor activity against advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and additional strategies are needed to improve outcomes. JDQ443 is a structurally unique covalent inhibitor of GDP-bound KRASG12C that forms novel interactions with the switch II pocket. JDQ443 potently inhibits KRASG12C-driven cellular signaling and demonstrates selective antiproliferative activity in KRASG12C-mutated cell lines, including those with G12C/H95 double mutations. In vivo, JDQ443 induces AUC exposure-driven antitumor efficacy in KRASG12C-mutated cell-derived (CDX) and patient-derived (PDX) tumor xenografts. In PDX models, single-agent JDQ443 activity is enhanced by combination with inhibitors of SHP2, MEK, or CDK4/6. Notably, the benefit of JDQ443 plus the SHP2 inhibitor TNO155 is maintained at reduced doses of either agent in CDX models, consistent with mechanistic synergy. JDQ443 is in clinical development as monotherapy and in combination with TNO155, with both strategies showing antitumor activity in patients with KRASG12C-mutated tumors. Significance: JDQ443 is a structurally novel covalent KRASG12C inhibitor with a unique binding mode that demonstrates potent and selective antitumor activity in cell lines and in vivo models. In preclinical models and patients with KRASG12C-mutated malignancies, JDQ443 shows potent antitumor activity as monotherapy and in combination with the SHP2 inhibitor TNO155. See related video: https://vimeo.com/720726054 This article is highlighted in the In This Issue feature, p. 1397

18 November 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ELEdwige Lorthiois
Edwige Lorthiois
MGMarc Gerspacher
Marc Gerspacher
KBKim S. Beyer
Kim S. Beyer
AVAndrea Vaupel
Andrea Vaupel
CLCatherine Leblanc
Catherine Leblanc
SCSimona Cotesta
Simona Cotesta

15 June 2017 in Chemical Science
Verified
Journal Article
Open access
PDF file
CBClaudio Bomio
Claudio Bomio
MKMikhail A. Kabeshov
Mikhail A. Kabeshov
ALArthur R. Lit
Arthur R. Lit
SLShing-Hing Lau
Shing-Hing Lau
JEJanna Ehlert
Janna Ehlert
SLSteven V. Ley
Steven V. Ley
By means of computational and experimental mechanistic studies the fundamental role of boroxines in the reaction between diazo compounds and boronic acids was elucidated. Consequently, a selective metal-free carbon–carbon homologation of aryl and vinyl boroxines using TMSCHN2, giving access to TMS-pinacol boronic ester products, was developed.

10 July 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BBBalázs Budai
Balázs Budai
AVAndrea Vaupel
Andrea Vaupel
CDCallum J. Dickson
Callum J. Dickson
KBKim S. Beyer
Kim S. Beyer
DGDaniel A. Guthy
Daniel A. Guthy
VEVeronika Ehmke
Veronika Ehmke

4 April 2023
Verified
Other
Open access
AWAndreas Weiss
Andreas Weiss
ELEdwige Lorthiois
Edwige Lorthiois
LBLouise Barys
Louise Barys
KBKim S. Beyer
Kim S. Beyer
CBClaudio Bomio-Confaglia
Claudio Bomio-Confaglia
SBSaskia M. Brachmann
Saskia M. Brachmann
Supplementary Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

4 April 2023
Verified
Other
Open access
AWAndreas Weiss
Andreas Weiss
ELEdwige Lorthiois
Edwige Lorthiois
LBLouise Barys
Louise Barys
KBKim S. Beyer
Kim S. Beyer
CBClaudio Bomio-Confaglia
Claudio Bomio-Confaglia
SBSaskia M. Brachmann
Saskia M. Brachmann
Supplementary Data from Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C